Inhibitor Therapeutics (OTCMKTS:INTI) versus SomaLogic (NASDAQ:SLGC) Head to Head Review

Inhibitor Therapeutics (OTCMKTS:INTIGet Rating) and SomaLogic (NASDAQ:SLGCGet Rating) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, valuation, profitability, institutional ownership and earnings.

Analyst Recommendations

This is a breakdown of current ratings for Inhibitor Therapeutics and SomaLogic, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Inhibitor Therapeutics 0 0 0 0 N/A
SomaLogic 0 0 4 0 3.00

SomaLogic has a consensus target price of $12.20, indicating a potential upside of 206.53%. Given SomaLogic’s higher probable upside, analysts plainly believe SomaLogic is more favorable than Inhibitor Therapeutics.

Volatility & Risk

Inhibitor Therapeutics has a beta of -0.63, indicating that its share price is 163% less volatile than the S&P 500. Comparatively, SomaLogic has a beta of 1.53, indicating that its share price is 53% more volatile than the S&P 500.


This table compares Inhibitor Therapeutics and SomaLogic’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Inhibitor Therapeutics N/A N/A -449.36%
SomaLogic -114.46% -16.76% -14.61%

Institutional & Insider Ownership

59.3% of SomaLogic shares are held by institutional investors. 4.6% of Inhibitor Therapeutics shares are held by company insiders. Comparatively, 12.9% of SomaLogic shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Inhibitor Therapeutics and SomaLogic’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Inhibitor Therapeutics N/A N/A -$300,000.00 N/A N/A
SomaLogic $81.63 million 8.94 -$87.55 million ($0.83) -4.80

Inhibitor Therapeutics has higher earnings, but lower revenue than SomaLogic.


SomaLogic beats Inhibitor Therapeutics on 7 of the 10 factors compared between the two stocks.

About Inhibitor Therapeutics

(Get Rating)

Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. It engages in the development of therapies for prostate and lung cancer utilizing SUBA-Itraconazole, an oral formulation of the drug itraconazole; and conducted a positive Phase 2b study of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed its name to Inhibitor Therapeutics, Inc. in August 2019. Inhibitor Therapeutics, Inc. was founded in 1992 and is based in Tampa, Florida.

About SomaLogic

(Get Rating)

SomaLogic, Inc. operates as a protein biomarker discovery and clinical diagnostics company in the United States. It develops slow off-rate modified aptamers (SOMAmers), which are modified nucleic acid-based protein binding reagents that are specific for their cognate protein; and offers proprietary SomaScan services, which provide multiplex protein detection and quantification of protein levels in complex biological samples. The company's SOMAmers/SomaScan technology enables researchers to analyze various types of biological samples for protein biomarker signatures, which can be utilized in drug discovery and development. Its SomaScan's biomarker discoveries help in diagnostic applications in various areas of diseases, including cardiovascular and metabolic disease, nonalcoholic steatohepatitis, wellness, and others. The company also provides SomaSignal research use only and laboratory-developed tests. It serves research and clinical customers with a focus on pharmaceutical and biotechnology companies, and academic research institutions, as well as facilitates drug development, analysis of clinical trials, and new human biology insights by assessing protein-protein and protein-gene networks. The company was incorporated in 1999 and is headquartered in Boulder, Colorado.

Receive News & Ratings for Inhibitor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inhibitor Therapeutics and related companies with's FREE daily email newsletter.